<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01086839</url>
  </required_header>
  <id_info>
    <org_study_id>NaCl 6.0%-nasal-CF</org_study_id>
    <nct_id>NCT01086839</nct_id>
  </id_info>
  <brief_title>Sino-nasal Inhalation of Sodium Chloride 6,0% in Patients With Cystic Fibrosis and Chronic Rhinosinusitis</brief_title>
  <official_title>Sino-nasal Inhalation of Sodium Chloride 6,0% in Patients With Cystic Fibrosis and Chronic Rhinosinusitis. A Multicenter, Randomized, Double-blind, Placebo-controlled, Prospective Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Jena</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Jena</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Rhinosinusitis disorders are almost regularly associated to Cystic Fibrosis (CF). The basic
      defect in CF is a dysfunction of chloride channels in exocrine glands which equally concerns
      upper airway mucosa. It leads to retention of secretions and consecutive chronic inflammation
      with bacterial superinfection.

      In CF rhinosinusitis can restrict quality of life, give cause to repeated ear, nose, and
      throat (ENT) surgery and accelerate disease progression by bacterial acquisition into the
      airways.

      The multicenter, randomized, double-blind, placebo-controlled, prospective clinical trial
      aims at the evaluation of a sino-nasal inhalation of sodium chloride 6% compared to isotonic
      saline with respect to ENT-related quality of life which is influenced by mucus retention and
      the resulting inflammation.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2010</start_date>
  <completion_date type="Actual">June 2013</completion_date>
  <primary_completion_date type="Actual">April 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in the Sino-nasal-outcome test SNOT-20 adapt CF</measure>
    <time_frame>days 1, 29, 57 and 85</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in the nasal lavage fluid and in the serological markers of inflammation</measure>
    <time_frame>days 1, 29, 57 and 85</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">69</enrollment>
  <condition>Cystic Fibrosis</condition>
  <condition>Rhinosinusitis</condition>
  <arm_group>
    <arm_group_label>sodium chloride 6%</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cross-Over! &quot;experimental&quot; (days 1 - 28), then Wash-Out (28 days),then &quot;placebo comparator&quot; (days 57 - 85).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>sodium chloride 0,9%</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Cross-Over! &quot;placebo comparator&quot; (days 1 - 28), then Wash-Out (28 days),then &quot;experimental&quot; (days 57 - 85).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>sodium chloride 6%</intervention_name>
    <description>one ampoule sodium chloride 6% per day
inhalation use
for 28 days</description>
    <arm_group_label>sodium chloride 6%</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>sodium chloride 0,9%</intervention_name>
    <description>one ampoule sodium chloride 0,9% per day
inhalation use
for 28 days</description>
    <arm_group_label>sodium chloride 0,9%</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject has a confirmed diagnosis of cystic fibrosis based on: 2 positive sweat
             chloride tests and/or genetic characterization

          -  Subject is 8 years of age or older

          -  informed consent of the patient or legal representative

          -  Women of childbearing potential are only included into the study, if they are using an
             effective method of birth control during the protocol (failure rate &lt;1% e.g. implants,
             combined oral contraceptives, injectables, some intrauterine devices, sexual
             abstinence or vasectomised partner)

        Exclusion Criteria:

          -  Subject has no chronic rhinosinusitis (European Position Paper on Rhinosinusitis and
             Nasal Polyps (EPOS-criteria)

          -  Subject has a critical condition defined as: forced expiratory volume at one second &lt;
             30% and / or arterial oxygen saturation &lt; 93% without O2-substitution; need of
             O2-substitution

          -  Subject had an ENT surgery within 6 months prior to study

          -  Subject participates in another clinical trial within 30 days prior to study entry
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>8 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jochen Mainz, M.D.</last_name>
    <role>Study Chair</role>
    <affiliation>University of Jena</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Zentrum für Kinder- und Jugendmedizin</name>
      <address>
        <city>Heidelberg</city>
        <state>Baden Würtemberg</state>
        <zip>69120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitäts-Kinderklinik</name>
      <address>
        <city>Tübingen</city>
        <state>Baden-Württemberg</state>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medizinische Klinik Innenstadt</name>
      <address>
        <city>München</city>
        <state>Bayern</state>
        <zip>80336</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Würzburg</name>
      <address>
        <city>Würzburg</city>
        <state>Bayern</state>
        <zip>97080</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zentrum für Kinder- und Jugendmedizin</name>
      <address>
        <city>Greifswald</city>
        <state>Brandenburg</state>
        <zip>17487</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>J.W. Goethe Universität - Abtl. Pneumologie</name>
      <address>
        <city>Frankfurt</city>
        <state>Hessen</state>
        <zip>60590</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinik für Kinder- und Jugendmedizin</name>
      <address>
        <city>Münster</city>
        <state>Nordrhein-Westfalen</state>
        <zip>48149</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum</name>
      <address>
        <city>Leipzig</city>
        <state>Sachsen</state>
        <zip>04103</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mukoviszidosezentrum der Friedrich-Schiller-Universität</name>
      <address>
        <city>Jena</city>
        <state>Thüringen</state>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charité Universitätsmedizin Berlin</name>
      <address>
        <city>Berlin</city>
        <zip>13353</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CF-Zentrum</name>
      <address>
        <city>Hamburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <reference>
    <citation>Mainz JG, Koitschev A. Management of chronic rhinosinusitis in CF. J Cyst Fibros. 2009 Jun;8 Suppl 1:S10-4. doi: 10.1016/S1569-1993(09)60005-9.</citation>
    <PMID>19460681</PMID>
  </reference>
  <reference>
    <citation>Mainz JG, Naehrlich L, Schien M, Käding M, Schiller I, Mayr S, Schneider G, Wiedemann B, Wiehlmann L, Cramer N, Pfister W, Kahl BC, Beck JF, Tümmler B. Concordant genotype of upper and lower airways P aeruginosa and S aureus isolates in cystic fibrosis. Thorax. 2009 Jun;64(6):535-40. doi: 10.1136/thx.2008.104711. Epub 2009 Mar 11.</citation>
    <PMID>19282318</PMID>
  </reference>
  <reference>
    <citation>Mainz JG, Schien C, Schiller I, Schädlich K, Koitschev A, Koitschev C, Riethmüller J, Graepler-Mainka U, Wiedemann B, Beck JF. Sinonasal inhalation of dornase alfa administered by vibrating aerosol to cystic fibrosis patients: a double-blind placebo-controlled cross-over trial. J Cyst Fibros. 2014 Jul;13(4):461-70. doi: 10.1016/j.jcf.2014.02.005. Epub 2014 Mar 1.</citation>
    <PMID>24594542</PMID>
  </reference>
  <reference>
    <citation>Mainz JG, Schädlich K, Schien C, Michl R, Schelhorn-Neise P, Koitschev A, Koitschev C, Keller PM, Riethmüller J, Wiedemann B, Beck JF. Sinonasal inhalation of tobramycin vibrating aerosol in cystic fibrosis patients with upper airway Pseudomonas aeruginosa colonization: results of a randomized, double-blind, placebo-controlled pilot study. Drug Des Devel Ther. 2014 Feb 10;8:209-17. doi: 10.2147/DDDT.S54064. eCollection 2014.</citation>
    <PMID>24596456</PMID>
  </reference>
  <verification_date>November 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 12, 2010</study_first_submitted>
  <study_first_submitted_qc>March 12, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 15, 2010</study_first_posted>
  <last_update_submitted>November 28, 2014</last_update_submitted>
  <last_update_submitted_qc>November 28, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 2, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Jena</investigator_affiliation>
    <investigator_full_name>PD Dr. Jochen G. Mainz</investigator_full_name>
    <investigator_title>PD Dr.</investigator_title>
  </responsible_party>
  <keyword>Cystic Fibrosis</keyword>
  <keyword>chronic rhinosinusitis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fibrosis</mesh_term>
    <mesh_term>Cystic Fibrosis</mesh_term>
    <mesh_term>Sinusitis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

